Literature DB >> 20503017

Is Fibroblast Growth Factor-23 a novel marker for phosphate burden in chronic kidney disease with prognostic implications?

Bernhard Bielesz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20503017     DOI： 10.1007/s00508-010-1365-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN： 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  19 in total

1.  Relation between serum phosphate level and cardiovascular event rate in people with coronary disease.

Authors:  Marcello Tonelli; Frank Sacks; Marc Pfeffer; Zhiwei Gao; Gary Curhan
Journal:  Circulation       Date:  2005-10-25       Impact factor: 29.690

2.  Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

Authors:  Junichiro J Kazama; Fuminori Sato; Kentaro Omori; Hitomi Hama; Suguru Yamamoto; Hiroki Maruyama; Ichiei Narita; Fumitake Gejyo; Takeyoshi Yamashita; Seiji Fukumoto; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

3.  Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Authors:  Shohei Nakanishi; Junichiro James Kazama; Tomoko Nii-Kono; Kentaro Omori; Takeyoshi Yamashita; Seiji Fukumoto; Fumitake Gejyo; Takashi Shigematsu; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

4.  Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.

Authors:  Heng Jung Hsu; Mai-Szu Wu
Journal:  Am J Med Sci       Date:  2009-02       Impact factor: 2.378

5.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

6.  Relationship between circulating FGF23 and total body atherosclerosis in the community.

Authors:  Majd A I Mirza; Tomas Hansen; Lars Johansson; Håkan Ahlström; Anders Larsson; Lars Lind; Tobias E Larsson
Journal:  Nephrol Dial Transplant       Date:  2009-05-09       Impact factor: 5.992

7.  Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.

Authors:  Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

8.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

9.  Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Authors:  Majd A I Mirza; Anders Larsson; Håkan Melhus; Lars Lind; Tobias E Larsson
Journal:  Atherosclerosis       Date:  2009-05-21       Impact factor: 5.162

10.  Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Christina L Wassel; Mary A Whooley
Journal:  Nephrol Dial Transplant       Date:  2009-12-27       Impact factor: 5.992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.